- AdaptHealth Corp AHCO delivered Q3 revenue of $756.5 million+15.8% Y/Y, beating consensus of $737.94 million.
- Adjusted EBITDA reached $160.2 million, +2.5% Y/Y.
- Steve Griggs, Chief Executive Officer, commented, “We delivered another solid quarter as we continue to be driven by strong demand in our HME and Sleep product lines with CPAP patient set-ups at or near record levels each month of the quarter and our Diabetes Benefits product line again posted double-digit growth.”
- The company reported earnings per share of $0.11, compared to $0.20 a year ago and the consensus of $0.31.
- Cash flow from operations was $107 million.
- Guidance: AdaptHealth revised revenue to $2.95 billion to $3.01 billion in FY22 compared to $2.84 billion to $3.04 billion earlier expected versus the consensus of $2.95 billion.
- Adjusted EBITDA guidance has been raised to $620-$650 million from $615-$675 million.
- Price promotion: AHCO shares are down 1.99% to $20.64 on the latest check Monday.
© 2022 Benzinga.de. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
